Riskpilot← Back to searchSign inGet full accessAPODANNORDIC PHARMAPACKAGING A/S
A/SActiveCVR 30541553Kigkurren 8C, 1. tvWholesale of other intermediate products · NACE 4686Est. 20089 employees
Revenue 2025
DKK 26M
-3% vs 2024
EBITDA margin
71.4%
-1% vs 2024
Equity ratio
76.1%
Financial strength
Net profit 2025
DKK 14,5M
-2% vs 2024
| Revenue | DKK 26M | -3% |
| EBITDA | DKK 18,6M | -1% |
| Net profit | DKK 14,5M | -2% |
| Total assets | DKK 58M | +11% |
| Equity | DKK 44,1M | +11% |
| Employees | 9 | — |
Legal name
APODANNORDIC PHARMAPACKAGING A/S
CVR number
30541553
Legal form
Aktieselskab
NACE code
4686 · Wholesale of other intermediate products
Founded
21. april 2008
Share capital
DKK 500.000
Employees
9 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem eller af en direktør eller af den samlede bestyrelse
Company purpose
Selskabets formål er at producere og distribuere pharma-emballager indenlands og udenlands samt enhver virksomhed som kan sidestilles hermed.
Address
Kigkurren 8C, 1. tv
Phone
+4532971555
Email
finance@apodanpharma.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 20.800 | 23.972 | 26.455 | 26.951 | 26.020 |
| Staff expenses | -5.854 | -6.928 | -7.506 | -8.201 | -7.444 |
| EBITDA | 14.947 | 17.043 | 18.949 | 18.750 | 18.576 |
| Depreciation & amort. | -200 | -200 | -217 | -250 | -267 |
| EBIT | 14.747 | 16.843 | 18.732 | 18.500 | 18.309 |
| Net financials | -120 | -138 | 234 | 553 | 338 |
| Profit before tax | 14.627 | 16.705 | 18.966 | 19.052 | 18.647 |
| Tax | 3.227 | 3.685 | 4.212 | 4.207 | 4.106 |
| Net profit | 11.400 | 13.020 | 14.754 | 14.845 | 14.541 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 34.617 | 52.391 | 45.238 | 52.404 | 58.011 |
| Equity | 23.772 | 29.991 | 34.746 | 39.591 | 44.132 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10.782 | 22.315 | 10.376 | 12.677 | 13.721 |
| Total debt | 10.782 | 22.315 | 10.376 | 12.677 | 13.721 |
EBITDA margin
71.4%
This company
15.8%
Market median
+352% vs market
20212025
Equity ratio
76.1%
This company
38.2%
Market median
+99% vs market
20212025
Return on equity
32.9%
This company
18.4%
Market median
+79% vs market
20212025
Net profit margin
55.9%
This company
8.1%
Market median
+590% vs market
20212025
Asset turnover
0.45×
This company
1.12×
Market median
-60% vs market
20212025
Debt / equity
0.31×
This company
0.62×
Market median
+50% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HS Chief Executive Officer | Chief Executive Officer | 2014 |
| Former (4) | ||
MM Management | Management | 2012 – 2014 |
KW Management | Management | 2016 – 2017 |
MN Management | Management | 2012 – 2016 |
ML Chief Executive Officer | Chief Executive Officer | 2009 – 2012 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2016 | |
| Chairman | 2017 | |
| Former (9) | ||
| Board of Directors | 2012 – 2014 | |
| Chairman | 2008 – 2012 | |
| Chairman | 2012 – 2015 | |
| Board of Directors | 2012 – 2012 | |
| Chairman | 2015 – 2017 | |
| Chairman | 2008 – 2008 | |
| Board of Directors | 2012 – 2016 | |
| Board of Directors | 2008 – 2012 | |
| Board of Directors | 2008 – 2009 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2012 | |
| Individual | 25–33.32% | 25% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of APODANNORDIC PHARMAPACKAGING A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mette Maria Feldt-Rasmussen | Management | 0 companies |
| Kálmán Wilhelm Patrick Petró | Management | 0 companies |
| Michaël Nicole Patrick Hillaert | Management | 0 companies |
| Henrik Schøsler Hansen | Chief Executive Officer | 0 companies |
| Morten Lodberg Petersen | Chief Executive Officer | 0 companies |
| Franciscus Adrianus Maria Gerardus Verbakel | Board of Directors | 0 companies |
| Henning Boysen | Chairman | 0 companies |
| Gerardus Johannes van Jeveren | Chairman | 0 companies |
| Jens Pauli Joensen | Board of Directors | 0 companies |
| Johannes Henricus Adrianus Stols | Chairman | 0 companies |
| Tom Carlos Buhmann | Chairman | 0 companies |
| Jan Peeters | Board of Directors | 0 companies |
| Søren Laursen | Board of Directors | 0 companies |
| Cornelia Neeltje de Jong | Board of Directors | 0 companies |
| Rafael Padilla Papaceit | Chairman | 0 companies |
| Henning Skinnerup Frandsen | Board of Directors | 0 companies |